Opzelura® Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
Incyte Presents Phase 1/2 Multidose Data for VGA039 at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
Incyte Announces Positive CHMP Opinion for Opzelura® Cream for the Treatment of Adults with Moderate Atopic Dermatitis
Incyte Japan Announces Approval of Minjuvi® in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab Combination Presented at the 2026 European Hematology Association Congress Plenary Showed Prolonged Progression Free Survival
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
Incyte's Pivotal frontMIND Trial Showed Tafasitamab Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
EnerCom Announces SM Energy as a Keynote Speaker at the 31st EnerCom Denver - The Energy Investment Conference, on August 19, 2026, in Denver, Colorado
